{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:04:29Z","timestamp":1791317069479,"version":"4.3.1"},"reference-count":72,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1016\/j.bcp.2006.04.010","type":"journal-article","created":{"date-parts":[[2006,5,3]],"date-time":"2006-05-03T13:55:46Z","timestamp":1146664546000},"page":"1485-1492","source":"Crossref","is-referenced-by-count":33,"title":["Molecular targets for emerging anti-tumor therapies for neurofibromatosis type 1"],"prefix":"10.1016","volume":"72","author":[{"given":"Joshua T.","family":"Dilworth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice M.","family":"Kraniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Wojtkowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Gibbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard F.","family":"Borch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Tainsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"John J.","family":"Reiners","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond R.","family":"Mattingly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bcp.2006.04.010_bib1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/00019052-200404000-00004","article-title":"Recent advances in neurofibromatosis type 1","volume":"17","author":"Arun","year":"2004","journal-title":"Curr Opin Neurol"},{"issue":"3","key":"10.1016\/j.bcp.2006.04.010_bib2","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0733-8619(01)00019-6","article-title":"Neurofibromatosis 1","volume":"20","author":"Lynch","year":"2002","journal-title":"Neurol Clin"},{"issue":"3A","key":"10.1016\/j.bcp.2006.04.010_bib3","first-page":"1699","article-title":"Malignant peripheral nerve sheath tumors (MPNST) in neurofibromatosis type 1 (NF1): diagnostic findings on magnetic resonance images and mutation analysis of the NF1 gene","volume":"25","author":"Friedrich","year":"2005","journal-title":"Anticancer Res"},{"issue":"4","key":"10.1016\/j.bcp.2006.04.010_bib4","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.pediatrneurol.2004.11.002","article-title":"Neurofibromatosis 1: from lab bench to clinic","volume":"32","author":"Ward","year":"2005","journal-title":"Pediatr Neurol"},{"issue":"2","key":"10.1016\/j.bcp.2006.04.010_bib5","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1006\/dbio.1994.1052","article-title":"Differential expression and tissue distribution of type I and type II neurofibromins during mouse fetal development","volume":"161","author":"Huynh","year":"1994","journal-title":"Dev Biol"},{"issue":"22","key":"10.1016\/j.bcp.2006.04.010_bib6","doi-asserted-by":"crossref","first-page":"9914","DOI":"10.1073\/pnas.88.22.9914","article-title":"Identification and characterization of the neurofibromatosis type 1 protein product","volume":"88","author":"DeClue","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.bcp.2006.04.010_bib7","first-page":"M13","article-title":"Neurofibromatosis type 1","volume":"1471","author":"Parada","year":"2000","journal-title":"Biochim Biophys Acta"},{"issue":"13","key":"10.1016\/j.bcp.2006.04.010_bib8","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1021\/bi027316z","article-title":"The mechanism of Ras GTPase activation by neurofibromin","volume":"42","author":"Phillips","year":"2003","journal-title":"Biochemistry"},{"key":"10.1016\/j.bcp.2006.04.010_bib9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1242\/jcs.1988.Supplement_10.12","article-title":"The Ras oncogenes","volume":"10","author":"Marshall","year":"1988","journal-title":"J Cell Sci Suppl"},{"issue":"8","key":"10.1016\/j.bcp.2006.04.010_bib10","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1021\/jm0305467","article-title":"Inhibitors of farnesyltransferase: a rational approach to cancer chemotherapy?","volume":"47","author":"Bell","year":"2004","journal-title":"J Med Chem"},{"issue":"6371","key":"10.1016\/j.bcp.2006.04.010_bib11","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/356713a0","article-title":"Aberrant regulation of Ras proteins in malignant tumour cells from type 1 neurofibromatosis patients","volume":"356","author":"Basu","year":"1992","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bcp.2006.04.010_bib12","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1124\/jpet.105.091454","article-title":"The mitogen-activated protein kinase\/extracellular signal-regulated kinase kinase inhibitor PD184352 (CI-1040) selectively induces apoptosis in malignant Schwannoma cell lines","volume":"316","author":"Mattingly","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.bcp.2006.04.010_bib13","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0090-3019(97)00356-X","article-title":"Neurofibromatosis type 1 peripheral nerve tumors: aberrant activation of the Ras pathway","volume":"51","author":"Feldkamp","year":"1999","journal-title":"Surg Neurol"},{"issue":"3","key":"10.1016\/j.bcp.2006.04.010_bib14","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/BF01233074","article-title":"Neurofibromatosis type 1 gene product (neurofibromin) associates with microtubules","volume":"19","author":"Gregory","year":"1993","journal-title":"Somat Cell Mol Genet"},{"issue":"4","key":"10.1016\/j.bcp.2006.04.010_bib15","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1523\/JNEUROSCI.21-04-01110.2001","article-title":"Schwann cell proliferative responses to cAMP and Nf1 are mediated by cyclin D1","volume":"21","author":"Kim","year":"2001","journal-title":"J Neurosci"},{"issue":"2","key":"10.1016\/j.bcp.2006.04.010_bib16","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nn792","article-title":"Neurofibromin regulates G protein-stimulated adenylyl cyclase activity","volume":"5","author":"Tong","year":"2002","journal-title":"Nat Neurosci"},{"issue":"11","key":"10.1016\/j.bcp.2006.04.010_bib17","first-page":"4132","article-title":"p15INK4b, p14ARF, and p16INK4a inactivation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors","volume":"9","author":"Perrone","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.bcp.2006.04.010_bib18","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/jnen\/64.1.74","article-title":"Expression patterns of cell cycle components in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors","volume":"64","author":"Agesen","year":"2005","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"10.1016\/j.bcp.2006.04.010_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnen\/64.1.1","article-title":"Tumor suppressor mutations and growth factor signaling in the pathogenesis of NF1-associated peripheral nerve sheath tumors: II. The role of dysregulated growth factor signaling","volume":"64","author":"Carroll","year":"2005","journal-title":"J Neuropathol Exp Neurol"},{"issue":"10","key":"10.1016\/j.bcp.2006.04.010_bib20","doi-asserted-by":"crossref","first-page":"7240","DOI":"10.1074\/jbc.M009202200","article-title":"Neurofibromin GTPase-activating protein-related domains restore normal growth in Nf1\u2212\/\u2212 cells","volume":"276","author":"Hiatt","year":"2001","journal-title":"J Biol Chem"},{"issue":"8","key":"10.1016\/j.bcp.2006.04.010_bib21","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1093\/hmg\/7.8.1261","article-title":"Selective disactivation of neurofibromin GAP activity in neurofibromatosis type 1","volume":"7","author":"Klose","year":"1998","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.bcp.2006.04.010_bib22","first-page":"315","article-title":"Enzymology and biology of CaaX protein prenylation","volume":"54","author":"Fu","year":"1999","journal-title":"Recent Prog Horm Res"},{"issue":"1","key":"10.1016\/j.bcp.2006.04.010_bib23","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1046\/j.1432-1327.1999.00815.x","article-title":"Farnesylation of Ras is important for the interaction with phosphoinositide 3-kinase gamma","volume":"266","author":"Rubio","year":"1999","journal-title":"Eur J Biochem"},{"issue":"1","key":"10.1016\/j.bcp.2006.04.010_bib24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1194\/jlr.R500012-JLR200","article-title":"Thematic review series: lipid posttranslational modifications. Farnesyl transferase inhibitors","volume":"47","author":"Basso","year":"2006","journal-title":"J Lipid Res"},{"issue":"15","key":"10.1016\/j.bcp.2006.04.010_bib25","doi-asserted-by":"crossref","first-page":"6722","DOI":"10.1128\/MCB.25.15.6722-6733.2005","article-title":"Individual palmitoyl residues serve distinct roles in H-Ras trafficking, microlocalization, and signaling","volume":"25","author":"Roy","year":"2005","journal-title":"Mol Cell Biol"},{"issue":"16","key":"10.1016\/j.bcp.2006.04.010_bib26","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.2174\/1381612013397258","article-title":"Ras signaling pathway proteins as therapeutic targets","volume":"7","author":"Adjei","year":"2001","journal-title":"Curr Pharm Des"},{"issue":"16","key":"10.1016\/j.bcp.2006.04.010_bib27","first-page":"3569","article-title":"Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype","volume":"55","author":"Yan","year":"1995","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.bcp.2006.04.010_bib28","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0092-8674(94)90308-5","article-title":"Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic","volume":"77","author":"Gibbs","year":"1994","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.bcp.2006.04.010_bib29","first-page":"1401","article-title":"HMG-CoA reductase inhibitors (statins) as anticancer drugs (review)","volume":"27","author":"Fritz","year":"2005","journal-title":"Int J Oncol"},{"issue":"21","key":"10.1016\/j.bcp.2006.04.010_bib30","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.cub.2005.09.043","article-title":"The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1","volume":"15","author":"Li","year":"2005","journal-title":"Curr Biol"},{"issue":"4","key":"10.1016\/j.bcp.2006.04.010_bib31","first-page":"478","article-title":"Farnesyltransferase inhibitors as anticancer agents: critical crossroads","volume":"7","author":"Doll","year":"2004","journal-title":"Curr Opin Drug Discov Develop"},{"issue":"3","key":"10.1016\/j.bcp.2006.04.010_bib32","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2174\/1389450053765833","article-title":"Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications","volume":"6","author":"Caraglia","year":"2005","journal-title":"Curr Drug Targets"},{"issue":"8","key":"10.1016\/j.bcp.2006.04.010_bib33","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1634\/theoncologist.10-8-565","article-title":"Development of farnesyl transferase inhibitors: a review","volume":"10","author":"Appels","year":"2005","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.bcp.2006.04.010_bib34","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/(SICI)1096-8628(19990326)89:1<14::AID-AJMG5>3.0.CO;2-4","article-title":"Hyperactive Ras as a therapeutic target in neurofibromatosis type 1","volume":"89","author":"Weiss","year":"1999","journal-title":"Am J Med Genet"},{"issue":"7","key":"10.1016\/j.bcp.2006.04.010_bib35","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1182\/blood.V94.7.2469.419a01_2469_2476","article-title":"In vitro and in vivo effects of a farnesyltransferase inhibitor on Nf1-deficient hematopoietic cells","volume":"94","author":"Mahgoub","year":"1999","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bcp.2006.04.010_bib36","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1128\/MCB.17.2.862","article-title":"Nf1-deficient mouse Schwann cells are angiogenic and invasive and can be induced to hyperproliferate: reversion of some phenotypes by an inhibitor of farnesyl protein transferase","volume":"17","author":"Kim","year":"1997","journal-title":"Mol Cell Biol"},{"issue":"12","key":"10.1016\/j.bcp.2006.04.010_bib37","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/S0960-894X(01)00292-X","article-title":"Synthesis and evaluation of GGPP geometric isomers: divergent substrate specificities of FTase and GGTase I","volume":"11","author":"Zahn","year":"2001","journal-title":"Bioorg Med Chem Lett"},{"issue":"2","key":"10.1016\/j.bcp.2006.04.010_bib38","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jmb.2004.08.056","article-title":"Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity","volume":"343","author":"Reid","year":"2004","journal-title":"J Mol Biol"},{"issue":"34","key":"10.1016\/j.bcp.2006.04.010_bib39","doi-asserted-by":"crossref","first-page":"12479","DOI":"10.1073\/pnas.0403413101","article-title":"A tagging-via-substrate technology for detection and proteomics of farnesylated proteins","volume":"101","author":"Kho","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.bcp.2006.04.010_bib40","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1124\/jpet.102.036061","article-title":"Potent suppression of proliferation of a10 vascular smooth muscle cells by combined treatment with lovastatin and 3-allylfarnesol, an inhibitor of protein farnesyltransferase","volume":"303","author":"Mattingly","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.bcp.2006.04.010_bib41","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ccr.2005.04.005","article-title":"Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy","volume":"7","author":"Sebti","year":"2005","journal-title":"Cancer Cell"},{"issue":"43","key":"10.1016\/j.bcp.2006.04.010_bib42","doi-asserted-by":"crossref","first-page":"41268","DOI":"10.1074\/jbc.M206573200","article-title":"Identification of a Ras palmitoyltransferase in Saccharomyces cerevisiae","volume":"277","author":"Lobo","year":"2002","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.bcp.2006.04.010_bib43","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1083\/jcb.200206120","article-title":"The yeast DHHC cysteine-rich domain protein Akr1p is a palmitoyl transferase","volume":"159","author":"Roth","year":"2002","journal-title":"J Cell Biol"},{"issue":"35","key":"10.1016\/j.bcp.2006.04.010_bib44","doi-asserted-by":"crossref","first-page":"31141","DOI":"10.1074\/jbc.M504113200","article-title":"DHHC9 and GCP16 constitute a human protein fatty acyltransferase with specificity for H- and N-Ras","volume":"280","author":"Swarthout","year":"2005","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.bcp.2006.04.010_bib45","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1158\/0008-5472.236.65.1","article-title":"Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes","volume":"65","author":"Dasgupta","year":"2005","journal-title":"Cancer Res"},{"issue":"16","key":"10.1016\/j.bcp.2006.04.010_bib46","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.2174\/1381612043384439","article-title":"MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors","volume":"10","author":"Sebolt-Leopold","year":"2004","journal-title":"Curr Pharm Des"},{"issue":"9","key":"10.1016\/j.bcp.2006.04.010_bib47","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1093\/jnen\/59.9.759","article-title":"Loss of neurofibromin is associated with activation of RAS\/MAPK and PI3K\/AKT signaling in a neurofibromatosis 1 astrocytoma","volume":"59","author":"Lau","year":"2000","journal-title":"J Neuropathol Exp Neurol"},{"issue":"15","key":"10.1016\/j.bcp.2006.04.010_bib48","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1038\/sj.emboj.7600309","article-title":"The Ras\/Raf\/ERK signalling pathway drives Schwann cell dedifferentiation","volume":"23","author":"Harrisingh","year":"2004","journal-title":"EMBO J"},{"issue":"10","key":"10.1016\/j.bcp.2006.04.010_bib49","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.4161\/cc.3.10.1187","article-title":"A novel role for mixed lineage kinase 3 (MLK3) in B-Raf activation and cell proliferation","volume":"3","author":"Chadee","year":"2004","journal-title":"Cell Cycle"},{"issue":"12","key":"10.1016\/j.bcp.2006.04.010_bib50","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S0898-6568(03)00087-1","article-title":"Cell surface receptors activate p21-activated kinase 1 via multiple Ras and PI3-kinase-dependent pathways","volume":"15","author":"Menard","year":"2003","journal-title":"Cell Signal"},{"issue":"9","key":"10.1016\/j.bcp.2006.04.010_bib51","doi-asserted-by":"crossref","first-page":"5139","DOI":"10.1073\/pnas.95.9.5139","article-title":"A role for Pak protein kinases in Schwann cell transformation","volume":"95","author":"Tang","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"10.1016\/j.bcp.2006.04.010_bib52","first-page":"191","article-title":"Signal therapy for RAS-induced cancers in combination of AG 879 and PP1, specific inhibitors for ErbB2 and Src family kinases, that block PAK activation","volume":"7","author":"He","year":"2001","journal-title":"Cancer J"},{"issue":"12","key":"10.1016\/j.bcp.2006.04.010_bib53","first-page":"1250","article-title":"Targeting the phosphatidylinositol-3 kinase\/Akt pathway for the treatment of cancer","volume":"6","author":"Kim","year":"2005","journal-title":"Curr Opin Investig Drugs"},{"issue":"15","key":"10.1016\/j.bcp.2006.04.010_bib54","first-page":"4507","article-title":"Epidermal growth factor receptor signaling pathways are associated with tumorigenesis in the Nf1:p53 mouse tumor model","volume":"62","author":"Li","year":"2002","journal-title":"Cancer Res"},{"issue":"24","key":"10.1016\/j.bcp.2006.04.010_bib55","doi-asserted-by":"crossref","first-page":"8573","DOI":"10.1073\/pnas.0503224102","article-title":"The NF1 tumor suppressor critically regulates TSC2 and Mtor","volume":"102","author":"Johannessen","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.bcp.2006.04.010_bib56","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/sj.onc.1207075","article-title":"Role of TC21\/R-Ras2 in enhanced migration of neurofibromin-deficient Schwann cells","volume":"23","author":"Huang","year":"2004","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.bcp.2006.04.010_bib57","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1172\/JCI7610","article-title":"Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models","volume":"105","author":"DeClue","year":"2000","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.bcp.2006.04.010_bib58","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ccr.2004.10.016","article-title":"Role for the epidermal growth factor receptor in neurofibromatosis-related peripheral nerve tumorigenesis","volume":"7","author":"Ling","year":"2005","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.bcp.2006.04.010_bib59","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/glia.10206","article-title":"Malignant peripheral nerve sheath tumor cell invasion is facilitated by Src and aberrant CD44 expression","volume":"42","author":"Su","year":"2003","journal-title":"Glia"},{"issue":"36","key":"10.1016\/j.bcp.2006.04.010_bib60","doi-asserted-by":"crossref","first-page":"5589","DOI":"10.1038\/sj.onc.1208730","article-title":"Activation of the neuregulin-1\/ErbB signaling pathway promotes the proliferation of neoplastic Schwann cells in human malignant peripheral nerve sheath tumors","volume":"24","author":"Stonecypher","year":"2005","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.bcp.2006.04.010_bib61","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/path.971","article-title":"Evaluating HER2 amplification and overexpression in breast cancer","volume":"195","author":"Bartlett","year":"2001","journal-title":"J Pathol"},{"issue":"6","key":"10.1016\/j.bcp.2006.04.010_bib62","first-page":"1281","article-title":"Expression of the ERBB2\/neu and neurofibromatosis type-1 gene products in reactive and neoplastic Schwann cell proliferation","volume":"13","author":"Schlegel","year":"1998","journal-title":"Int J Oncol"},{"issue":"3","key":"10.1016\/j.bcp.2006.04.010_bib63","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/BF01052920","article-title":"Amplification and differential expression of members of the erbB-gene family in human glioblastoma","volume":"22","author":"Schlegel","year":"1994","journal-title":"J Neurooncol"},{"issue":"1","key":"10.1016\/j.bcp.2006.04.010_bib64","doi-asserted-by":"crossref","first-page":"96","DOI":"10.4161\/cbt.3.1.643","article-title":"The Tyr-kinase inhibitor AG879, that blocks the ETK-PAK1 interaction, suppresses the RAS-induced PAK1 activation and malignant transformation","volume":"3","author":"He","year":"2004","journal-title":"Cancer Biol Ther"},{"issue":"5569","key":"10.1016\/j.bcp.2006.04.010_bib65","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1126\/science.1068452","article-title":"Neurofibromas in NF1: Schwann cell origin and role of tumor environment","volume":"296","author":"Zhu","year":"2002","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bcp.2006.04.010_bib66","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1084\/jem.191.1.181","article-title":"Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo","volume":"191","author":"Ingram","year":"2000","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.bcp.2006.04.010_bib67","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/S0002-9440(10)63233-6","article-title":"Loss of the Nf1 tumor suppressor gene decreases fas antigen expression in myeloid cells","volume":"164","author":"Hiatt","year":"2004","journal-title":"Am J Pathol"},{"issue":"12","key":"10.1016\/j.bcp.2006.04.010_bib68","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1172\/JCI19195","article-title":"Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1+\/\u2212 mast cells","volume":"112","author":"Yang","year":"2003","journal-title":"J Clin Invest"},{"issue":"12","key":"10.1016\/j.bcp.2006.04.010_bib69","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1172\/JCI200320503","article-title":"It takes two to tango: mast cell and Schwann cell interactions in neurofibromas","volume":"112","author":"Viskochil","year":"2003","journal-title":"J Clin Invest"},{"issue":"10","key":"10.1016\/j.bcp.2006.04.010_bib70","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1212\/WNL.58.10.1461","article-title":"Plexiform neurofibromas in NF1: toward biologic-based therapy","volume":"58","author":"Packer","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2006.04.010_bib71","doi-asserted-by":"crossref","unstructured":"Clark MK, Reigard SA, Wojtkowiak JW, Chirco R, Mathieu P, Reiners Jr JJ, Mattingly RR, Borch RF, Gibbs RA. Synthesis, biochemical, and cellular evaluation of farnesyl monophosphate prodrugs as farnesyltransferase inhibitors, submitted for publication, 2006.","DOI":"10.1021\/jm0701829"},{"key":"10.1016\/j.bcp.2006.04.010_bib72","unstructured":"Dilworth JT, Kraniak JM, Mathieu P, Reiners Jr JJ, Tainsky MA, Mattingly RR. Deregulated N-Ras increase epidermal growth factor receptor expression and activity in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cells, submitted for publication, 2006."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295206002462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295206002462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,7]],"date-time":"2023-05-07T09:04:21Z","timestamp":1683450261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295206002462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":72,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["S0006295206002462"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2006.04.010","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2006,11]]}}}